Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 22:22:100381.
doi: 10.1016/j.eclinm.2020.100381. eCollection 2020 May.

Pre-treatment HIV drug resistance testing cost-effectiveness

David Amc van de Vijver  1 , Brooke E Nichols  2   3
Affiliations

Pre-treatment HIV drug resistance testing cost-effectiveness

David Amc van de Vijver et al. EClinicalMedicine. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. van de Vijver reports grants from Gilead Sciences, grants and other from ViiV, grants from Johnson & Johnson, grants from Merck, outside the submitted work; Dr. Nichols has nothing to disclose.

References

    1. Hamers R.L., Schuurman R., Sigaloff K.C., Wallis C.L., Kityo C., Siwale M. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012;12(4):307–317. - PubMed
    1. Boender T.S., Hoenderboom B.M., Sigaloff K.C.E., Hamers R.L., Wellington M., Shamu T. Pretreatment HIV Drug Resistance Increases Regimen Switches in Sub-Saharan Africa. Clin Infect Dis. 2015;61(11):1749–1758. - PubMed
    1. Chung M.H., McGrath C.J., Beck I.A., Levine M., Milne R.S., So I. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial. Lancet HIV. 2020;7(4):e104–e112. - PMC - PubMed
    1. Duarte H.C., Babigumira J.B., Enns E.A. Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women. EClinicalMedicine. 2020 doi: 10.1016/j.eclinm.2020.100355. - DOI - PMC - PubMed
    1. Orkin C., Arasteh K., Hernández-Mora M.G., Pokrovsky V., Overton E.T., Girard P.-.M. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020;382(12):1124–1135. - PubMed

LinkOut - more resources